Clinical Trial Update: Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immunogenicity and safety of Pentaxim given as three-dose primary vaccination with an 18-month booster.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Infection
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• Pentaxim

Snippet

Sponsor: Sanofi | Conditions: Diphtheria, Tetanus | Phase 3 | Status: COMPLETED